Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

Conception and design: Uwe Platzbecker, Xiaosha Zhang, Kenneth M. Attie

Provision of study materials or patients: Uwe Platzbecker, Katharina S. Götze, Philipp Kiewe, Ulrich Germing, Karin Mayer, Markus Radsak, Thomas Wolff, Joerg Chromik, Katja Sockel, Thomas Illmer, Haifa Kathrin Al‐Ali, Gerda Silling, Aristoteles Giagounidis

Collection and assembly of data: Uwe Platzbecker, Katharina S. Götze, Philipp Kiewe, Ulrich Germing, Karin Mayer, Markus Radsak, Thomas Wolff, Joerg Chromik, Katja Sockel, Uta Oelschlägel, Detlef Haase, Thomas Illmer, Haifa Kathrin Al-Ali, Gerda Silling, Aristoteles Giagounidis

Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Uwe Platzbecker

Honoraria: Celgene/Jazz, AbbVie, Curis, Geron, Janssen

Consulting or Advisory Role: Celgene/Jazz, Novartis, BMS GmbH & Co KG

Research Funding: Amgen (Inst), Janssen (Inst), Novartis (Inst), BerGenBio (Inst), Celgene (Inst), Chris (Inst)

Patents, Royalties, Other Intellectual Property: Part of a patent for a TFR-2 antibody

Travel, Accommodations, Expenses: Celgene

Katharina S. Götze

Honoraria: BMS

Consulting or Advisory Role: Celgene/BMS, AbbVie, Servier/Pfizer

Research Funding: BMS

Philipp Kiewe

Consulting or Advisory Role: Roche, Bristol Myers Squibb/Celgene, BeiGene, Amgen, Pfizer, AstraZeneca/Merck

Speakers’ Bureau: Excellence in Oncology

Ulrich Germing

Honoraria: Celgene/BMS, Jazz Pharmaceuticals, Novartis

Consulting or Advisory Role: Celgene

Research Funding: Celgene (Inst), Novartis (Inst)

Karin Mayer

Stock and Other Ownership Interests: Roche Pharma AG, Autolus Therapeutics, Merck Serono, Pfizer, Gilead Sciences, BMSi

Markus Radsak

Honoraria: Celgene

Consulting or Advisory Role: Takeda, Novartis, CORAT

Thomas Wolff

Honoraria: AstraZeneca, Apogepha, AbbVie, Incyte, Seagan

Consulting or Advisory Role: Roche

Katja Sockel

Honoraria: Bristol Myers Squibb/Celgene, Novartis, Alexion Pharmaceuticals, SOBI

Consulting or Advisory Role: Takeda, Novartis

Travel, Accommodations, Expenses: Jazz Pharmaceuticals, Celgene/Bristol Myers Squibb

Detlef Haase

Honoraria: Novartis, Jazz Pharmaceuticals, Takeda, Celgene/Bristol Myers Squibb

Research Funding: Celgene/BMSD

Travel, Accommodations, Expenses: Celgene/Bristol Myers Squibb

Thomas Illmer

Consulting or Advisory Role: Novartis, AstraZeneca, AbbVie

Haifa Kathrin Al-Ali

Honoraria: Novartis, BMSi, Incyte (Inst), Takeda, Pfizer, AbbVie

Consulting or Advisory Role: Novartis, BMSi, AbbVie

Research Funding: Novartis (Inst), BMSi (Inst), Incyte (Inst)

Travel, Accommodations, Expenses: BMSi, Novartis

Gerda Silling

Travel, Accommodations, Expenses: AbbVie

Joseph G. Reynolds

Employment: Acceleron Pharma, Inc, C4 Therapeutics

Stock and Other Ownership Interests: Acceleron Pharma, Inc

Xiaosha Zhang

Employment: Acceleron Pharma, Inc

Stock and Other Ownership Interests: Acceleron Pharma, Inc

Kenneth M. Attie

Employment: Acceleron Pharma, Inc, Imara

Leadership: Imara

Jeevan K. Shetty

Employment: Bristol Myers Squibb/Celgene

Stock and Other Ownership Interests: Bristol Myers Squibb/Celgene

Aristoteles Giagounidis

Stock and Other Ownership Interests: Novartis, Roche

Honoraria: Amgen, Novartis, Bristol Myers Squibb/Celgene

Consulting or Advisory Role: Bristol Myers Squibb/Celgene

No other potential conflicts of interest were reported.

留言 (0)

沒有登入
gif